[Federal Register Volume 61, Number 93 (Monday, May 13, 1996)]
[Notices]
[Page 22066]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 96-11909]



-----------------------------------------------------------------------


DEPARTMENT OF HEALTH AND HUMAN SERVICES

Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The invention referenced below is owned by an agency of the 
U.S. Government and is available for licensing in the U.S. in 
accordance with 35 U.S.C. 207 to achieve expeditious commercialization 
of results of federally funded research and development.
    U.S. Patent 4,788,181 issued on November 29, 1988 and entitled ``5-
Substituted-2',3'-Dideoxycytidine Compounds with Anti-HTLV-III 
Activity''--5-substituted-2',3'-dideoxycytidine analogs and their 
phosphorylated derivatives are effective inhibitors of HTLV-III/LAV 
(HIV) infection, especially in the brain. Although the parent compound 
2',3'-dideoxycytidine can scarcely enter the central nervous system, 
2',3'-dideoxy-5-fluorocytidine readily penetrates the blood-brain 
barrier and, thus, is more effective against the AIDS virus in the 
brain.
    The invention claimed in this patent is available for licensing on 
either an exclusive or nonexclusive basis.
    Interested parties should respond by August 12, 1996.

ADDRESSES: Licensing information and a copy of the issued patent may be 
obtained by contacting Robert Benson at the Office of Technology 
Transfer, National Institutes of Health, 6011 Executive Boulevard, 
Suite 325, Rockville, Maryland 20852-3804 (telephone 301/496-7056 ext 
267; fax 301/402-0220).

    Dated: May 2, 1996.
Barbara M. McGarey,
Deputy Director, Office of Technology Transfer.
[FR Doc. 96-11909 Filed 5-10-96; 8:45 am]
BILLING CODE 4140-01-M